Anticholesteremic Agents
"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 2 | 0 | 2 | | 2002 | 3 | 0 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 2 | 3 | 5 | | 2006 | 1 | 0 | 1 | | 2007 | 3 | 5 | 8 | | 2008 | 0 | 1 | 1 | | 2009 | 5 | 3 | 8 | | 2010 | 0 | 1 | 1 | | 2011 | 2 | 1 | 3 | | 2012 | 6 | 2 | 8 | | 2013 | 2 | 0 | 2 | | 2014 | 2 | 0 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2017 | 4 | 2 | 6 | | 2018 | 2 | 4 | 6 | | 2019 | 5 | 1 | 6 | | 2020 | 7 | 1 | 8 | | 2021 | 5 | 0 | 5 | | 2022 | 6 | 0 | 6 | | 2023 | 5 | 0 | 5 | | 2024 | 3 | 4 | 7 | | 2025 | 6 | 0 | 6 | | 2026 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Jukema JW, Van Neer NJ, Szarek M, Cobbaert C, Bittner VA, Schwertfeger M, Bhatt DL, Fazio S, Goodman SG, Harrington RA, Stevanovic I, White HD, Steg PG, Schwartz GG. Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome. Eur Heart J. 2026 Oct 26; 47(40):6008-6017.
-
Nicholls SJ, Nelson AJ, Ray KK, Ditmarsch M, Kling D, Hsieh A, Szarek M, Kastelein JJ, Davidson MH. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026 Jul 07; 47(26):3404-3414.
-
Saseen JJ, Dixon DL. Nonstatins for LDL-C lowering: An expansion whose time has come. J Clin Lipidol. 2026 Sep; 20(9S):22-24.
-
Inia JA, Zhang LH, Keijzer N, Worms N, van Nieuwkoop-van Straalen A, Ditmarsch M, de Kleer M, Jukema JW, Kastelein JJP, Szarek M, van den Hoek AM, Stokman G, Pieterman EJ, Princen HMG. Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background. J Lipid Res. 2026 May; 67(5):101028.
-
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Goldberg AC, Brunham LR, Wuerdeman E, Neild AL, Kling D, Hsieh A, Butters J, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Szarek M, Balinskaite V, Davidson MH. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
Landmesser U, Ray KK, Raal FJ, Garcia Conde L, Han J, Koenig W, Leiter LA, Schwartz GG, Wright RS. Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials. J Am Soc Nephrol. 2026 Jul 01; 37(7):1497-1506.
-
Davidson MH, Szarek M, Scheltens P, Vijverberg E, Hsieh A, Ditmarsch M, Kling D, Curcio D, Nicholls SJ, Ray KK, Cummings JL, Kastelein JJ. Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. J Prev Alzheimers Dis. 2026 Jan; 13(1):100394.
-
Myerson M, Warden BA, Saseen JJ, Paparodis R. Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction. J Am Heart Assoc. 2025 10 21; 14(20):e044134.
-
Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M, Trompet S, Bhatt DL, Bittner VA, Diaz R, Fazio S, Stevanovic I, Goodman SG, Harrington RA, White HD, Steg PG, Schwartz GG, Cobbaert CM. Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arterioscler Thromb Vasc Biol. 2025 11; 45(11):2111-2123.
-
Nicholls SJ, Nelson AJ, Ray KK, Ballantyne CM, Ditmarsch M, Kling D, Hsieh A, Szarek M, Kastelein JJ, Davidson MH. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|